CMS warns state Medicaid programs on hepatitis c drug restrictions

| November 6, 2015

article image
Demonstrating concern over prescription drug costs, the Obama administration wrote state Medicaid programs that they may be violating federal law by restricting access to hepatitis C medicines. At the same time, the Centers for Medicare and Medicaid Services wrote four drug makers asking for information about pricing arrangements with insurers and pharmacy benefits managers.

Spotlight

Frontier Health

Frontier Health's vision is to establish and provide accessible, high quality care. Frontier Health, a 501(c) 3, is the area’s leading provider of mental health, substance abuse, co-occurring, developmental and intellectual disabilities, recovery and vocational rehabilitation services for adults, children and youth at 64 sites in Northeast Tennessee and Southwest Virginia. Frontier Health's mission is to provide quality services that encourage people to achieve their full potential. To provide those services, Frontier’s 1,005 employees traveled 1.74 million miles during FY 2014-15 in a 12,000-square-mile coverage area for 48,862 individuals. Frontier Health also provides an adult residential treatment for addiction and/or co-occurring disorders, services for individuals who are deaf or hard of hearing, domestic violence victims, youth in crisis, runaways, foster care and adoption services.

OTHER ARTICLES

Roche Prepares to Launch COVID-19 Antibody Test System

Article | April 17, 2020

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease. This morning, Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2, the virus that causes COVID-19. Roche is eying May for the launch of the test in Europe and is in talks with the U.S Food and Drug Administration for emergency approval of the system. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms, the company said. Roche noted that as more information becomes available about immunity levels to COVID-19, society can return to a sense of normal much more quickly. Roche’s test will join a number of other antibody tests that have recently come on the market. Earlier this month the U.S. Food and Drug Administration approved the first blood test for COVID-19 antibodies.

Read More

Pfizer Won’t Win the Coronavirus Pharma War

Article | March 6, 2020

Shares of Pfizer jumped more than 6% on Wednesday, after the company announced a plan to test some of its antiviral products as a potential treatment for the coronavirus from China. More than 35 million shares traded on the news — about 48% more than normal — as investors looked for any positive news from the pharma community after the recent selloff. So, does this mean that Pfizer stock is turning the corner?

Read More

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | April 3, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | April 1, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Spotlight

Frontier Health

Frontier Health's vision is to establish and provide accessible, high quality care. Frontier Health, a 501(c) 3, is the area’s leading provider of mental health, substance abuse, co-occurring, developmental and intellectual disabilities, recovery and vocational rehabilitation services for adults, children and youth at 64 sites in Northeast Tennessee and Southwest Virginia. Frontier Health's mission is to provide quality services that encourage people to achieve their full potential. To provide those services, Frontier’s 1,005 employees traveled 1.74 million miles during FY 2014-15 in a 12,000-square-mile coverage area for 48,862 individuals. Frontier Health also provides an adult residential treatment for addiction and/or co-occurring disorders, services for individuals who are deaf or hard of hearing, domestic violence victims, youth in crisis, runaways, foster care and adoption services.

Events